The FDA on Fri­day is­sued two si­mul­ta­ne­ous cys­tic fi­bro­sis ap­provals for Ver­tex Phar­ma­ceu­ti­cals but in­clud­ed ...

Jan 2. Highlights: Novo's CagriSema data disappoints, Merck licenses GLP-1 from Hansoh Pharma, and Trump's FTC picks show ...

House Speaker Johnson and GOP push for narrow spending bill without healthcare reforms as midnight shutdown deadline looms; ...

Pfizer scored an accelerated approval Friday to bring its BRAF inhibitor to first-line colorectal cancer patients.

Rhythm Pharmaceuticals received FDA approval to market its genetic obesity drug Imcivree for children as young as 2 years old ...

Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...

Sofinnova Investments, one of the longest-standing biotech investment firms, has penciled in plans for a new $550 million ...

Applied Therapeutics CEO Shendelman exits; CFO Funtleyder becomes interim CEO after FDA rejects govorestat. Company withdraws ...

→ Yu­ki Abe will step in to re­place the late Toshi­nori Agat­suma on Jan. 1 as head of … Get free access to a limited number ...

Tracer Biotechnologies raises $10M Series A for tumor DNA monitoring tech; partners with AstraZeneca for clinical trials. CEO ...

Aadi Bioscience sells cancer drug Fyarro to Kaken Pharmaceutical for $100M, licenses three ADCs from WuXi Biologics and ...

Syncromune, a biotech startup working on combination immunotherapies, has put together a $100 million Series A, the company ...